Cheplapharm - We invest in global brand products of medicine.

Cheplapharm is an internationally active pharmaceutical company based in Germany, specializing in the acquisition and sustainable continuation of established brand medicines.

Through an asset-light business model and strategic acquisitions, the company continuously expands its portfolio, which consists of patent-free but proven medicines. Cheplapharm operates globally and works with a network of partners and suppliers to ensure efficient distribution and supply.

With a strong focus on sustainable growth, regulatory expertise, and market adaptation, Cheplapharm positions itself as a reliable partner in the pharmaceutical industry.

The successful business model makes Cheplapharm the first Unicorn (startup with a billion-dollar valuation) of our startup scene.

Business Model

CHEPLAPHARM has more than 3,200 registrations worldwide and distributes around 150 branded products in different therapeutic areas – from cardiology and oncology to gastroenterology.

The company also offers medications for the treatment of sleep disorders, mental illnesses, and severe infectious diseases. CHEPLAPHARM stands for the highest product quality and a broadly diversified portfolio in the pharmaceutical industry.

Target Groups

CHEPLAPHARM addresses various target groups with its broad portfolio of pharmaceutical products:

• Patients: Individuals who rely on proven medications for the treatment of diseases in areas such as cardiology, oncology, or gastroenterology.
• Healthcare Providers: Physicians, pharmacists, and other healthcare professionals who require high-quality medications for their patients.
• Pharmaceutical Companies: Research-oriented pharmaceutical companies that want to entrust established brand products to reliable hands in order to focus on innovations.
• Investors: Individuals and institutions interested in sustainable investment opportunities in the pharmaceutical industry.
• Potential Employees: Professionals who want to work for a globally operating company in the pharmaceutical industry.

These diverse target groups reflect CHEPLAPHARM's commitment to making a positive contribution in various areas of healthcare and economy.

CHEPLAPHARM has undergone impressive development since its founding in 1998 and achieved numerous successes.

• Global expansion through acquisitions: CHEPLAPHARM has acquired the rights to around 150 branded medicines and medical products from international pharmaceutical companies. Notable acquisitions included Distraneurin, Rohypnol, and Vesanoid.
• Awards for corporate management: In May 2019, CHEPLAPHARM received the "Axia Best Managed Companies Award" and was thus counted among Germany's best-managed companies. This award was again conferred in 2020, underscoring the company's sustainable leadership quality.
• Successful capital market activities: In July 2018, CHEPLAPHARM concluded new credit facilities totaling 780 million euros to refinance existing loans and finance future product purchases.
• Entrepreneurial recognition: Sebastian Braun, CEO of CHEPLAPHARM, was awarded the prestigious "EY Entrepreneur of the Year" in the family business category in November 2024. cheplapharm.com

The company employs around 800 employees from 40 different nations, who work together in a dynamic and multicultural environment.